We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Pharmacotherapy update: fludarabine in the treatment of non-Hodgkin's lymphoma.
- Authors
Shvidel L; Cohn M; Sigler E
- Abstract
Fludarabine, a purine nucleoside analogue, is considered as the most active drug in chronic lymphocytic leukemia. This review summarizes current knowledge concerning the mechanism of action, pharmacological properties, clinical activity and toxicity of fl udarabine in the treatment of non-Hodgkin's lymphoma. A literature search on fl udarabine for lymphomas was undertaken using MEDLINE databases. Clinical data shows that fl udarabine alone and as a component of combination chemotherapy is effective in patients with various types of non-Hodgkin's lymphoma, particularly in follicular lymphoma. The most commonly used combinations are with cyclophosphamide and/or mitoxantrone. Fludarabine-based regimens are highly active in both previously untreated and relapsed indolent lymphomas. The results of the chemotherapy are considerably improved with the addition of rituximab. Fludarabine is generally well tolerated. Myelosuppression and infections, including opportunistic varieties, are the most frequent adverse effects. Indications for fl udarabine and treatment regimens for lymphoma patients are discussed.
- Publication
Clinical Medicine: Therapeutics, 2009, Issue 1, p359
- ISSN
1179-1713
- Publication type
Journal Article